Analisis efektivitas biaya pengobatan pasien diabetes tipe 2 dengan terapi glibenklamid DAN metformin pasien bpjs rawat inap DI rsud sukoharjo tahun 2017
Abstract
Diabetes mellitus is a metabolic disease characterized by hyperglycemia caused by abnormal metabolism of carbohydrates, fats and proteins; and can cause chronic complications such as microvascular, macrovascular and neuropathic. Treatment of DM type 2 in RSUD Sukoharjo use metformin and glibenklamide. The aim of this study was to analyze the treatment cost-effectiveness of hospitalize patients with DM type 2 using Metformin and Glibenklamide. The study was an observational cross-sectional method according to the hospital's perspective using secondary data in January-December 2017 period regarding the treatment of 62 BPJS class-III DM type 2 patients. The data included demographic data, length of stay and total costs. A total of 32 patients class III BPJS use Metformin and 30 patients class III BPJS use glibenklamide. Patients age ranged from 36-65 years, geriatric patients. The effectiveness of drug therapy was measured based on GDS. Statistical used independent t-test. The results showed that metformin therapy were more cost-effective with the percentage of therapy effectiveness 90,63% while glibenklamide 70%, average total cost of metformin therapy was Rp. 2.821. 531 and glibenklamide Rp. 3.099.659. ACER Metformin value was Rp. 31.132,417 while glibenclamide Rp. 44.280,843. Metformin more cost-effective than glibenklamide.
Keyword : Cost Effectiveness Analysis, diabetic, metformin, glibenklamide
How strong is the evidence?
Evidence Hub reads this as a cross-sectional. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 32 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.